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ABSTRACT
Objectives: To determine weight change patterns in
Scottish patients 2 years after diagnosis of type 2
diabetes and to examine these in association with
medium-term glycaemic, mortality and cardiovascular
outcomes.
Setting: Using a retrospective cohort design, ethical
approval was obtained to link the Scottish diabetes care
database to hospital admission and mortality records.
Participants: 29 316 overweight/obese patients with
incident diabetes diagnosed between 2002 and 2006
were identified with relevant information for ≥2 years.
Primary and secondary outcome measures:
Weight records over time provided intrapatient weight
change and variation and glycated haemoglobin (HbA1c)
gave measures of glycaemic control. These characteristics
and demographic variables at diagnosis were linked with
notifications of death (2–5 years after diagnosis) and
cardiovascular events (0–5 year after diagnosis).
Results: By 2 years, 36% of patients had lost ≥2.5% of
their weight. Increasing age, being female and a higher
body mass index at diagnosis were associated with larger
proportions of weight lost (p<0.001). Multivariable
modelling showed that inadequate glycaemic control at
2 years was associated with being younger at baseline,
being male, having lower levels of obesity at diagnosis,
gaining weight or being weight stable with weight change
variability, and starting antidiabetic medication. While
weight change itself was not related to mortality or
cardiovascular outcomes, major weight variability was
independently associated with poorer survival and
increased cardiovascular outcome risks, as was
deprivation.
Conclusions: Our results suggest that weight loss or
being weight stable with little weight variability early after
diabetes diagnosis, are associated with better glycaemic
control and we identified groups less able to lose weight.
With respect to mortality and cardiovascular outcomes,
although weight change at 2 years was a weak predictor,
major weight variability appeared to be the more relevant
factor.
INTRODUCTION
Counselling for body weight reduction for
patients with obesity is key within type 2 dia-
betes management guidelines.1 2 The Look
AHEAD trial showed weight reduction
improved long-term glycaemic control over
4 years in patients with a median duration of
5 years of diabetes.3 Similarly, Feldstein et al4
in the USA, along with others,5 found an
association between initial weight loss with
improved glycaemic and blood pressure
control during the fourth year of follow-up
in a cohort of 2574 newly diagnosed patients
with type 2 diabetes, despite weight regain
after initial weight loss. Authors have specu-
lated that the initial period after diagnosis of
type 2 diabetes may be critical for early
Strengths and limitations of this study
▪ This representative study uses the national
Scottish diabetes register to study all patients
with type 2 diabetes, providing a substantial data
set with up to 5 years of follow-up.
▪ We used novel methods to study the impact of
weight change patterns on glycaemic control,
and link these to Scottish data for mortality and
cardiovascular disease.
▪ We had sufficient statistical power to identify
groups (men, younger patients, those with lower
levels of obesity at diagnosis and higher levels of
deprivation) who might particularly benefit from
structured weight loss interventions.
▪ There were insufficient numbers of patients on
newer antidiabetic medications, such as gliptins
and glucagon-like peptide-1 receptor agonists, to
analyse their effects.
▪ The influences of blood pressure and lipid
control were not incorporated into the analyses.
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glycaemic control6 and for applying weight loss interven-
tions,4 to improve glycaemia and risk factor control.
Feldstein et al7 findings also mirror those of the Finnish
Diabetes Prevention Study and the Diabetes Prevention
Program trials, where long-term prevention of diabetes
was seen in the lifestyle intervention arms, again despite
some weight regain.8 9 While, the Look AHEAD and
Finnish Diabetes Prevention trials were unable to dem-
onstrate a reduction in cardiovascular events,10 11 there
have been some cost benefits seen especially for obese
patients who lose weight.12
There is little information about variability of weight
change in type 2 diabetes and the long-term outcomes.
Zoppini et al13 found an association between variability
in body weight and glycaemic control over a 10-year
follow-up period and saw increased mortality in older
patients with type 2 diabetes. Weight change in people
with diabetes may be unintentional and related to poor
glycaemic control and the use of antihyperglycaemic
treatment.14 Thus, the main objective of this study is to
investigate whether early changes after diagnosis in
weight and glycaemic control, along with their variabil-
ity, influence morbidity and mortality in type 2 diabetes,
as well as treatment and glycaemic control.
METHODS
In 2000, a population-based database, derived from
primary and secondary care, was initiated as a register of
people with diabetes across Scotland in the Scottish
Care Information Diabetes Collaboration (SCI-DC) data-
base15 (SCI-Diabetes since 2012). This database contains
demographic and clinical data covering over 99.5% of
people with a diagnosis of diabetes in Scotland. A 2011
extract of the SCI-DC data set was linked to hospital
admission, cancer registration and mortality records by
the Information Services Division (ISD) of National
Health Service (NHS) National Services Scotland. This
data set and a retrospective cohort design approach was
used to examine the main objectives.
Study population
From the SCI-DC database, we extracted information on
adult patients (>18 years) newly diagnosed with type 2
diabetes between 2002 and 2006. Patients with type 2 dia-
betes are a heterogeneous group; consequently we used
rigorous inclusion/exclusion criteria (figure 1). People
with a record of previous cancer, thyroid disease or on
oral steroids were excluded. We selected these particular
co-existing diseases from an otherwise numerous list as
being the most likely for this patient group to promote
weight loss. Excluded too were patients who had a body
mass index (BMI) <25 kg/m2 at diagnosis (ie, normal
weight or less). Further, we excluded those who died or
moved out of Scotland within the first 2 years after diag-
nosis (to reduce effects of illness-related weight loss), had
a low glycated haemoglobin (HbA1c; <6.0%) at diagnosis
or were prescribed insulin within 18 months of diagnosis
(to avoid including those more likely to have type 1 dia-
betes or who had had type 2 diabetes for a while prior to
formal diagnosis). Given our interest in weight change
patterns, those with only one recorded weight measure or
with <21 months follow-up were also excluded. Successive
records were examined and all data cleaned.
Study variables
We used characteristic variables recorded at diagnosis,
that is, gender, age, smoking status (unknown, current,
ex, never) and deprivation, using the five-point Scottish
Index of Multiple Deprivation (SIMD)16 ranging from
‘most deprived’ to ‘least deprived’, the latter being our
reference group. SIMD is an area-based measure which
combines 38 indicators across seven domains, namely:
income, employment, health, education, skills and train-
ing, housing, geographic access and crime. Ethnicity was
not included in these analyses since this registry is pri-
marily white European,17 and while normally an import-
ant variable our focus was on weight change patterns.
Also included were successive measures of weight,
BMI, drug treatment and HbA1c from diagnosis
onwards to examine weight change and glycaemic
control relationships. HbA1c was reported as percen-
tages rather than in mmol/mol in the database. Where
possible, we have given both. Record linkage allowed
investigation of further relationships of these with subse-
quent all-cause mortality and cardiovascular outcomes
(myocardial infarction (MI), congestive heart failure
(CHF), peripheral vascular disease and cerebrovascular
disease identified using the International Classification
of Diseases, 10th Edition (ICD-10) codes from hospital
and death records).
Baseline and follow-up epochs
Individuals’ baseline was set as the date of weight
recorded within ±3 months of diagnosis. Similarly, the
weight record closest to 12, 24, 36 and 60 months within
a ±6-month window represented follow-up weight at 1, 2,
3 and 5 years, respectively. Pragmatically, the HbA1c
measure recorded closest to the date of the selected
weight record, within a ±3-month window, was matched
to that weight. While the analyses were conducted on
each of these epochs, this paper concentrates on the
2-year follow-up.
Weight change and variation categories, and four weight
change pattern groups
Percentage weight change was calculated overall and
within each specified follow-up period (1, 2, 3 and
5 years) then categorised as follows:
Loss: 10% or more, <10% to 5%, <5% to 2.5%;
Stable: Loss of 2.5% up to gain of 2.5%;
Gain: >2.5% to 5%, >5% to 10%, 10% or more.
The weight stable group is based on the National
Institute for Health and Care Excellence (NICE) Public
Health Guidance no 53,18 which indicates that a 3%
long-term weight loss is associated with health benefits.
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The coefficient of variation (cv) of weight change for
each patient was calculated for the different follow-up
periods to measure variability or cycling of weight, as
follows:
cv= standard deviation of weight ðper patientÞ=
meanweight ðper patientÞ
then given the skewness of the distribution of the
number of visits (median=6; IQR 4–9)) this was cate-
gorised into:
Little (<2.5%),
Some (2.5 to <5%),
Moderate (5 to <10%) and
Large (10%+).
While weight loss and gain are expected to be variable,
variation in the weight stable group may be detrimental.
Consequently this group was further divided into stable
and steady over each follow-up period thus providing just
four broad weight patterns: loss, stable-steady (little vari-
ation cv<2.5%), stable-cyclic (cv≥2.5%) and gain.
Figure 1 Summarising clinical and data cleaning exclusions. BMI, body mass index; FU, follow-up; HbA1c, glycated
haemoglobin.
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Antidiabetic medication groupings
Medication needs considering when relating weight
change and patterns of weight change to glycaemic
control, since some glucose-lowering treatments induce
weight gain or loss. While in practice many combina-
tions of medication may be expected, we concentrated
on specific groupings using a ladder approach based on
drugs most likely to induce weight gain. Hence, within a
follow-up period, a patient ever on insulin was grouped
within the ‘insulin combinations’ group. The ‘sulfony-
lurea (SU) combinations’ group included anyone ever
prescribed SUs during that time epoch but not insulin.
Those on glitazones with or without metformin but not
insulin or SU combinations were considered together,
leaving those on metformin alone, and finally those on
no antidiabetic drugs over the follow-up duration.
Glycaemic control
Glycaemic control definitions vary. While <48 mmol/
mol (or 6.5%) is an absolute target, we defined ‘control’
as HbA1c≤53 mmol/mol (or 7%), a commonly used
clinical classification.5 6
Statistical analyses
All analyses were conducted on SPSS V.23 and/or SAS
V.9.3 (SAS Institute, Cary, North Carolina, USA).
Initially, characteristics of those included and excluded
were compared. For the included patients, summary sta-
tistics for initial weight and HbA1c levels are investigated
alongside patient characteristics. Associations of the
derived weight change categories with initial patient
characteristics were examined. Since not all participants
had the same number of follow-up epochs, missing data
were assessed and the baseline summaries were consid-
ered according to those in each epoch, although we
concentrated on just the second year follow-up period.
All the above basic comparisons used analysis of variance
or independent t-tests, as appropriate. The progression
of treatment combinations over time is graphically
described, along with the relationship between the
weight change categories (at 2 years) with initial HbA1c,
and with the average changes seen in HbA1c, the latter
also being split according to antidiabetic medication.
Proportions of those in each of the four weight change
patterns were also considered in relation to glycaemic
‘control’ having taken antidiabetic medication into
account.
Relative risks (RRs) of glycaemic ‘control’ for the
weight change groups were estimated using log-binomial
regression models (since the proportion ‘in control’ vs
‘not in control’ was similar) except for non-converging
models, where Poisson regression models with robust
variance were used.19 Weight change, weight variability,
antidiabetic medication and weight change–medication
interactions for each follow-up period were predictor
variables, adjusted for patient characteristics at diagnosis,
BMI, sex, smoking status and deprivation.
All-cause mortality is a single time event, while the car-
diovascular outcomes are multiple events. For the latter,
only the first event was analysed. Cox regression was con-
ducted on deaths between 2 and 5 years (prior to
2 years were excluded to limit the potential for reverse
causality from conditions that cause weight loss and
increase mortality) and 0–5 years for cardiovascular first
events (reverse causality is less of a concern for non-fatal
cardiovascular events). These were modelled against:
weight change, cv, antidiabetic medication and weight
change–medication interactions, all at 2 years (consid-
ered to be a reasonable weight change assessment
period); and adjusted for HbA1c control at 2 years, and
patient characteristics at diagnosis, as given above. Those
who had not died by the ISD extraction date were cen-
sored at that date (1 December 2013) as were those who
had not experienced a cardiovascular event, unless the
patient had died before, in which case the date of death
was used as the cardiovascular event censored time.
Owing to the many analyses being performed and the
larger sample sizes, significance levels were reduced to
p<0.001 to assess the RRs for glycaemic control and the
HRs for the cardiovascular outcomes.
RESULTS
Baseline characteristics
Originally 81 990 patients diagnosed with type 2 diabetes
were recorded on the register between 2002 and 2006.
After exclusions, the final sample had 29 316 cases with
240 150 records (figure 1). Excluded patients were
slightly older (59.4 vs 58.4 years), more likely to be men
(56.0% vs 54.4%), with a higher proportion with
unknown smoking status (17.3% vs12.7%), but fewer
were classed as deprived using SIMD16 categories: 46%
in the two most deprived categories compared with
49.4% in the two least deprived categories. Although
these were statistically significant, they were not consid-
ered clinically important (apart from smoking status),
especially since the main aim was to investigate weight
patterns and their potential effect.
For the included participants, the median (IQR)
follow-up period was 5.2 years (3.8–6.2) with between 2
and 69 visits. At diagnosis for these patients (n=29 316),
54% were men, mean age was 58 years (SD=12), mean
HbA1c was 67 mmol/mol or 8.3% (SD=1.9) and mean
BMI was 33.2 (SD=6.0) kg/m2. Men had slightly lower
mean BMI (32.3, SD=5.3) than women (34.2, SD=6.6).
Table 1 shows younger patients and those most deprived
to be clinically and statistically significantly heavier.
Males were also statistically heavier than women but no
more than expected given height differences. There
were no differences in weight across the different
smoking groups.
Table 1 also shows that mean HbA1c at diagnosis
(n=22 781, not all included patients had an HbA1c
measurement at diagnosis) was 66 mmol/mol or 8.2%
(SD=1.9). This differed between men and women and
between age, smoking, deprivation and BMI groups.
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However, only age and BMI differences were of clinical
importance: younger patients (<40 years) had higher
mean baseline HbA1c level than older (≥60 years)
patients (72 mmol/mol or 8.7%, SD=2.0 vs 64 mmol/
mol or 8.0%, SD=1.9). Those who were overweight (≥25
BMI<30 kg/m2) had slightly higher mean baseline
HbA1c (66 mmol/mol or 8.3%, SD=2.05) than those
who were obese (BMI≥30 kg/m2) where it ranged
between 65 and 66 mmol/mol or 8.1% and 8.2%.
Missing data
Patient numbers fell with follow-up. However, patients
still alive with relevant weight (n=20 856) and HbA1c
(n=16 225) data after 2 years had similar diagnosis
weight and HbA1c summary statistics (bottom line,
table 1), thus still reflective of our original database. By
2 years, 29% and 37% of patients had missing data for
weight (kg) and HbA1c, respectively (see online supple-
mentary table S1). However, 99% of those with weight
and HbA1c measures at 2 years also had information for
the other variables of interest.
Weight change
Of the 20 856 patients with 2-year follow-up data, the
mean percentage weight change was small at −0.7±6.7%.
At a population level, BMI was also relatively unchanged,
baseline mean BMI was 33.2 kg/m2 (SD=6.0) at baseline
and 32.8 kg/m2 (SD=5.9) after 2 years. However, the per-
centage weight change categories over time show many
were either weight stable or had weight loss: at 2 years,
around 36% had lost weight (2.5% or more), with 21%
losing more than 5% and 7% achieving 10% or more
weight loss (see online supplementary figure S1a).
These proportions were even higher after 5 years with
41% having weight loss, 28% with >5% weight loss and
11% with 10%+ weight loss. Variation of this weight
change was, as expected, largest for those with the most
weight change and increased with follow-up (see online
supplementary figure S1b).
Demographics associated with weight change
More women (40%) than men (32%) lost ≥2.5% of
their body weight 2 years after diagnosis of diabetes with
sex differences persisting even after 5 years (47% vs
35%, respectively). A larger per cent weight loss was sig-
nificantly associated with higher BMI at diagnosis (see
online supplementary table S2). Age at diagnosis was
also significant with weight loss (mean age of those with
10% weight gain was 56 years (SD=12.6) compared with
59 years (SD=11.0) for those with 10% weight loss).
Table 1 Summary statistics of weight (kg) and HbA1c (%) at diagnosis by patient characteristics
Characteristics
Baseline weight (kg) Baseline HbA1c (%)
Mean SD n p Value* Mean SD n p Value*
Sex
Male 97.7 18.0 15 955 <0.001 8.3 1.9 12 394 <0.001
Female 86.8 18.2 13 361 8.1 1.9 10 387
Age group (years)
<40 105.3 22.3 1793 <0.001 8.7 2.0 1436 <0.001
40–60 97.5 19.5 13 283 8.4 1.9 10 398
≥60 86.7 15.6 14 240 8.0 1.9 10 947
Smoking
Unknown 92.9 19.2 3719 0.167 8.1 1.9 2806 <0.001
Current 92.5 18.7 6705 8.3 1.9 5252
Ex-smoker 93.1 18.0 7817 8.1 1.9 6083
Never smoked 92.5 19.5 11 075 8.2 1.9 8640
Deprivation category†
Most deprived 93.2 19.8 7380 <0.001 8.3 1.9 5808 <0.001
2 92.7 19.0 6917 8.2 1.9 5392
3 93.2 18.8 5557 8.2 1.9 4271
4 92.7 18.3 4905 8.2 1.9 3757
Least deprived 91.4 17.8 4173 8.1 1.9 3252
BMI category ( kg/m2)
25–29.9 78.3 10.0 10 153 8.3 2.1 7923 <0.001
30–34.9 91.0 11.4 10 120 8.2 1.9 7873
35–39.9 102.9 13.0 5327 8.2 1.8 4135
40+ 122.3 18.8 3716 8.2 1.8 2850
Total 92.7 18.9 29 316 8.2 1.9 22 781
Patients with 2 years follow-up 92.5 18.7 20 856 8.2 1.9 16 225
*p Values are from ANOVA or independent t-test as appropriate.
†Categories of SIMD,16 baseline weight n=28 932, baseline weight n=22 480.
ANOVA, analysis of variance; BMI, body mass index; HbA1c, glycated haemoglobin; SIMD, Scottish Index of Multiple Deprivation.
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Associations between weight change and HbA1c change
For each follow-up period, the mean HbA1c at diagnosis
was lowest for those who lost weight or were weight
stable. Conversely, diagnosis HbA1c was highest for
those who later gained weight (figure 2).
Next considered were patterns of weight change with
glycaemic control in conjunction with the specified
antidiabetic medication groups. These groups accounted
for 99.8% of all patients after 2 years. Figure 3 shows the
proportions of these groups; those on no antidiabetic
drugs initially represented around 56% of the sample
declining to 19% by the fifth year. Metformin on its own
was the most common drug with little variation for sole
prescription (between 30% and 38%) over time, while
the proportion of patients receiving any SU combination
increased with time (12–32%). Glitazone prescription
(with or without metformin) and insulin (with or
without any other drug) also increased from virtually no
prescriptions to around 10% after 5 years.
The mean HbA1c significantly dropped within the
first year (p<0.001) regardless of treatment but crept
back up over time (table 2); online supplementary table
S3 splits this for differing weight categories showing sig-
nificantly that the mean HbA1c was lowest for those with
10% weight loss and largest for those with 10% weight
gain regardless of follow-up time.
Figure 4 shows changes in HbA1c, 2 years after diagno-
sis of diabetes, by the different weight change categories
and treatment groupings (associated sample sizes, see
online supplementary table S4).
After 2 years, HbA1c reductions were associated with
good weight loss and/or drug regimens. This pattern
was similar for all follow-up periods (not shown).
Patients with improved HbA1c levels tended to have
weight loss or stability (78% after 1 year, 73% by the
second year and 68% after 5 years) and were mostly on
either metformin or no drugs (87% year 1, 73% years
2–5). Those on combinations of SUs or glitazones had
greater improvement in HbA1c and also tended to gain
weight. The exceptions were some patients on insulin, as
seen in the top left of figure 4, who despite substantial
Figure 2 Average HbA1c (%) at diagnosis with weight
change for different follow-up periods (1, 2, 3 and 5 years).
HbA1c, glycated haemoglobin.
Figure 3 Antidiabetic medication group proportions over follow-up.
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weight loss (>5%) had increased HbA1c, possibly sug-
gesting weight loss induced by poorly controlled
diabetes.
The downward parabola-shaped response of HbA1c to
per cent weight change (figure 4), except for those on
insulin, also highlights the three broad bands of weight
change (loss, stability and gain), giving rise to the investi-
gation concentrating on ‘weight loss’ (more than 2.5%
loss), ‘weight stable’ (between ±2.5%) and ‘weight gain’
(more than 2.5% gain).
Recall that the weight stable group was further divided
to reflect variability into the ‘weight stable-steady’ and
‘weight stable-cyclic’ categories.
Using HbA1c≤7% or 53 mmol/mol, as glycaemic
control, we found that at diagnosis 36% were ‘in
control’, improving to 55% within the first year, drop-
ping to 51% for those after 2 years and levelling off to
around 47% thereafter. Figure 5 illustrates this after
2 years, in conjunction with antiglycaemic medication
and weight change pattern group. Greater proportions
of people who lost weight, regardless of treatment,
achieved glycaemic control at 2 years compared with
those who gained or had stable weight.
Models for each follow-up period were derived using
HbA1c ‘in control’/‘not in control’ as a binary depend-
ent variable. The four weight change patterns (loss,
stable-steady, steady-cyclic and gain), the five variability
cv categories and treatment combinations were included
as predictors. In addition, an interactive term of weight
change with treatment was included to accommodate
Figure 4 Mean HbA1c levels for each treatment combination
and weight change category (at 2 years’ follow-up). HbA1c,
glycated haemoglobin.
Figure 5 Percentage of those in glycaemic control
(HbA1c≤53 mmol/mol (or 7%)) at 2 years’ follow-up, by weight
change pattern group and treatment. HbA1c, glycated
haemoglobin.
Table 2 Summary statistics of glycated haemoglobin
(HbA1c) at baseline and then each time epoch
HbA1c per
cent N Minimum Maximum Mean SD
Baseline 22 781 6.00 18.00 8.19 1.93
After year 1 15 953 4.10 16.90 7.21 1.28
After year 2 18 591 4.10 17.00 7.33 1.36
After year 3 17 427 4.00 16.60 7.39 1.40
After year 5 12 644 4.10 16.60 7.49 1.50
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Table 3 Multivariable RR for HbA1c>53 mmol/mol over specified follow-up periods (significance taken at p≤0.001)
Risk of
HbA1c>53 mmol/mol
(not in control)
1-year follow-up
Not in control n=7139
2-year follow-up
Not in control n=8969
3-year follow-up
Not in control n=8661
5-year follow-up
Not in control n=6553
Variable n RR (95% CL)* p Value n RR (95% CL)† p Value n RR (95% CL)† p Value n RR (95% CL)† p Value
AT diagnosis variables
Age 15 757 0.996 (0.995,
0.997)
<0.001 18 344 0.991 (0.990,
0.992)
<0.001 17 176 0.990 (0.988,
0.992)
<0.001 12 401 0.990 (0.988,
0.991)
<0.001
BMI, kg/m2
30–34.9 5466 1.17 (1.09, 1.26) <0.001 6336 1.13 (1.061, 1.20) <0.001 5959 1.10 (1.03, 1.17) 0.003 4225 1.11 (1.04, 1.20) 0.003
35–39.9 2816 1.09 (1.04, 1.14) <0.001 3311 1.07 (1.03, 1.11) 0.001 3084 1.05 (1.01, 1.09) 0.021 2224 1.06 (1.01, 1.11) 0.016
40+ 1970 1.10 (1.05, 1.16) <0.001 2233 1.06 (1.01, 1.11) 0.019 2145 1.06 (1.01, 1.11) 0.018 1578 1.06 (1.00, 1.11) 0.036
25–29.9 (ref) 5505 1 6464 1 5988 1 4374 1
Sex
Male 8483 0.98 (0.96, 1.02) 0.316 9949 1.01 (0.98, 1.04) 0.576 9301 1.02 (0.99, 1.05) 0.310 6795 1.05 (1.02, 1.09) 0.002
Female (ref) 7274 1 8395 1 7875 1 5606 1
Smoking status at diagnosis
Unknown 1940 1.05 (1.00, 1.10) 0.033 2353 0.95 (0.91, 0.99) 0.026 2153 0.97 (0.93, 1.02) 0.235 1423 0.99 (0.94, 1.04) 0.613
Current 3572 1.04 (1.01, 1.084) 0.025 4193 0.99 (0.95, 1.02) 0.392 3860 0.99 (0.95, 1.03) 0.532 2835 0.98 (0.94, 1.02) 0.278
Ex 4350 1.02 (0.99, 1.06) 0.291 4980 0.97 (0.94, 1.00) 0.086 4613 0.95 (0.92, 0.99) 0.019 3332 0.97 (0.94, 1.01) 0.193
Never (ref) 5895 1 6818 1 6550 1 4811 1
Deprivation at diagnosis
Most 3915 1.00 (0.95, 1.05) 0.999 4593 0.96 (0.91, 1.00) 0.050 4289 1.00 (0.95, 1.04) 0.883 3229 1.01 (0.96, 1.07) 0.717
2 3696 1.04 (0.99, 1.09) 0.173 4306 0.98 (0.94, 1.03) 0.461 4076 1.00 (0.95, 1.05) 0.992 2944 1.00 (0.95, 1.06) 0.884
3 2981 1.03 (0.98, 1.09) 0.222 3490 0.99 (0.94, 1.04) 0.652 3283 1.00 (0.96, 1.05) 0.907 2338 1.05 (1.00, 1.12) 0.062
4 2795 1.04 (0.98, 1.09) 0.218 3253 0.99 (0.94, 1.04) 0.670 2992 1.01 (0.96, 1.06) 0.659 2086 1.02 (0.96, 1.08) 0.511
Least (ref) 2370 1 2702 1 2536 1 1804 1
Time EPOCH variables
Anti-DM med groups
Insulin Comb 0 – – 329 4.06 (3.53, 4.67) <0.001 635 4.28 (3.80, 4.82) <0.001 1151 3.93 (3.39, 4.57) <0.001
SU Comb 3050 2.97 (2.66, 3.31) <0.001 4437 3.39 (3.06, 3.74) <0.001 4933 3.21 (2.88, 3.57) <0.001 4494 3.08 (2.67, 3.56) <0.001
Glit Comb 738 3.54 (3.11, 4.03) <0.001 1159 3.44 (3.04, 3.88) <0.001 1361 2.95 (2.59, 3.36) <0.001 1147 2.60 (2.19, 3.09) <0.001
Met only 6003 2.18 (1.98, 2.41) <0.001 6915 2.24 (2.03, 2.48) <0.001 6247 2.11 (1.89, 2.35) <0.001 3745 1.90 (1.64, 2.21) <0.001
None (ref) 5966 1 5504 1 4000 1 1864 1
Weight change
S-S 3330 1.17 (1.01, 1.35) 0.031 3347 1.24 (1.07, 1.45) 0.005 1636 1.04 (0.86, 1.25) 0.694 1671 1.00 (0.73, 1.38) 0.982
S-C 3538 1.39 (1.23, 1.56) <0.001 3535 1.43 (1.27, 1.62) <0.001 2824 1.31 (1.13, 1.53) <0.001 1768 1.44 (1.17, 1.78) 0.001
Gain 3538 1.75 (1.54, 1.97) <0.001 4956 1.74 (1.54, 1.97) <0.001 5076 1.62 (1.41, 1.86) <0.001 3969 1.57 (1.28, 1.93) <0.001
Loss (ref) 5466 1 6506 1 6414 1 4993 1
CV
2.5% to <5% 4686 0.88 (0.85, 0.92) <0.001 6613 0.90 (0.87, 0.93) <0.001 7074 0.91 (0.88, 0.94) <0.001 5903 0.92 (0.89, 0.96) <0.001
5% to <10% 1794 0.77 (0.72, 0.83) <0.001 2532 0.77 (0.73, 0.81) <0.001 2732 0.79 (0.75, 0.83) <0.001 2564 0.80 (0.76, 0.84) <0.001
10%+ 321 0.68 (0.57, 0.80) <0.001 392 0.64 (0.55, 0.73) <0.001 441 0.65 (0.57, 0.73) <0.001 382 0.74 (0.66, 0.83) <0.001
<2.5% (ref) 8956 1 8807 1 6929 1 3552 1
Continued
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Table 3 Continued
Risk of
HbA1c>53 mmol/mol
(not in control)
1-year follow-up
Not in control n=7139
2-year follow-up
Not in control n=8969
3-year follow-up
Not in control n=8661
5-year follow-up
Not in control n=6553
Variable n RR (95% CL)* p Value n RR (95% CL)† p Value n RR (95% CL)† p Value n RR (95% CL)† p Value
Anti-DM med/weight change interaction
Insulin comb×S-S 0 – – 41 0.76 (0.60, 0.97) 0.027 82 0.80 (0.64, 1.01) 0.058 121 0.89 (0.64, 1.25) 0.509
Insulin comb×S-C 0 – – 48 0.74 (0.61, 0.90) 0.002 66 0.73 (0.61, 0.87) 0.001 128 0.77 (0.61, 0.96) 0.020
Insulin comb×gain 0 – – 140 0.62 (0.52, 0.74) <0.001 317 0.59 (0.50, 0.69) <0.001 542 0.69 (0.55, 0.85) 0.001
SU comb×S-S 725 0.79 (0.67, 0.94) 0.007 891 0.68 (0.58, 0.80) <0.001 881 0.85 (0.70, 1.04) 0.105 684 0.94 (0.68, 1.30) 0.714
SU comb×S-C 493 0.89 (0.78, 1.02) 0.102 698 0.82 (0.70, 0.94) 0.005 710 0.87 (0.75, 1.02) 0.090 577 0.85 (0.68,1.06) 0.148
SU comb×gain 1175 0.66 (0.57, 0.76) <0.001 1747 0.62 (0.51, 0.71) <0.001 1983 0.65 (0.56, 0.75) <0.001 1825 0.71 (0.57,0.87) 0.001
Glit comb×S-S 189 0.74 (0.61, 0.90) 0.003 262 0.63 (0.51, 0.77) <0.001 260 0.79 (0.63, 1.00) 0.047 186 0.81 (0.56, 1.16) 0.247
Glit comb×S-C 127 0.81 (0.69, 0.95) 0.010 146 0.81 (0.69, 0.95) 0.012 163 0.87 (0.72, 1.05) 0.145 137 0.88 (0.69, 1.14) 0.342
Glit comb×gain 257 0.53 (0.44, 0.64) <0.001 483 0.53 (0.45, 0.62) <0.001 606 0.59(0.49, 0.70) <0.001 518 0.56 (0.44, 0.71) <0.001
Met comb×S-S 1410 1.01 (0.87, 1.18) 0.856 1365 0.89 (0.75, 1.05) 0.150 1076 1.01 (0.82, 1.23) 0.959 487 1.10 (0.79, 1.54) 0.578
Met comb×S-C 1140 1.08 (0.95, 1.23) 0.223 1298 1.04 (0.91, 1.19) 0.540 1008 1.09 (0.93, 1.28) 0.540 548 1.05 (0.84, 1.32) 0.656
Met only×gain 1114 0.84 (0.73, 0.96) 0.013 1402 0.83 (0.72, 0.95) 0.006 1246 0.84 (0.72, 0.98) 0.006 684 1.01 (0.81, 1.25) 0.964
No anti-DM med
and/or weight loss (ref)
9127 1 9823 1 8778 1 5964 1
Constant 0.37 (0.21, 0.28) <0.001 0.85 (0.30, 0.40) <0.001 0.71 (0.33, 0.44) <0.001 0.81 (0.32, 0.44) <0.001
White background areas indicate significant increased risk of being ‘out of control’ at p≤0.001 (to counter the large sample sizes).
Bold typeface indicates significant protective effect against being ‘out of control’ at p≤0.001 (to counter the large sample sizes).
All predictors in the table are included as adjuster variables.
*Binomial regression using generalised linear model with a log link.
†Poisson regression using generalised linear model with a log link (sandwich variance estimates) used if the binomial regression did not converge.
Anti-DM med, antidiabetic medication; BMI, body mass index; CL, confidence limit; comb, combinations (not including previous drugs in table); CV, coefficient of variation; Glit, glitazone or
glitazone with metformin; HbA1c, glycated haemoglobin; Met, metformin; ref, reference group; RR, relative risk; S-C, weight stable/cyclic; S-S, weight stable/steady; SU, sulphonylurea.
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Table 4 Multivariable HRs for all-cause mortality and cardiovascular outcomes
HR for health
outcome after
0–5 years
All-cause mortality
2–5 years
743 events n=17 711
MI
0–5 years
616 events n=18 236
CHF
0–5 years
425 cases n=18 192
PVD
0–5 years
300 events n=18 298
CD
0–5 years
360 events n=18 264
HR (95% CL) p Value HR (95% CL) p Value HR (95% CL) p Value HR (95% CL) p Value HR (95% CL) p Value
Age at diagnosis 1.12 (1.11, 1.13) <0.001 1.04 (1.03, 1.05) <0.001 1.08 (1.06, 1.09) <0.001 1.06 (1.04, 1.07) <0.001 1.06 (1.05, 1.08) <0.001
HbA1c ‘not in control’ 0.96 (0.82, 1.13) 0.632 1.09 (0.91, 1.29) 0.359 1.09 (0.88, 1.34) 0.428 1.01 (0.79, 1.30) 0.952 1.05 (0.84, 1.32) 0.654
At 2 years ‘in control’* (ref) 1 1 1 1 1
BMI at diagnosis, kg/m2 0.013 <0.001 0.558 0.044
30–34.9 0.94 (0.79, 1.11) 0.455 1.00 (0.83, 1.21) 0.966 1.14 (0.91, 1.44) 0.259 0.93 (0.72, 1.20) 0.577 0.97 (0.77, 1.23) 0.810
35–39.9 1.09 (0.87, 1.36) 0.456 1.21 (0.96, 1.52) 0.106 1.57 (1.19, 2.08) 0.002 0.83 (0.58, 1.20) 0.325 1.07 (0.79, 1.46) 0.643
40+ 1.47 (1.12, 1.93) 0.005 0.85 (0.61, 1.19) 0.348 2.17 (1.55, 3.02) <0.001 0.73 (0.44, 1.21) 0.219 0.49 (0.29, 0.83) 0.008
25–29.9 (ref) 1 1 1 1 1
Sex, male 1.607 (1.37, 1.86) <0.001 2.26 (1.89, 2.69) <0.001 2.21 (1.79, 2.72) <0.001 1.85 (1.44, 2.37) <0.001 1.36 (1.09, 1.69) 0.006
Smoking status at diagnosis <0.001 <0.001 0.001 <0.001 0.271
Unknown 1.50 (1.19, 1.90) 0.001 1.56 (1.18, 2.06) 0.002 1.40 (1.02, 1.932) 0.040 2.57 (1.64, 4.02) <0.001 1.10 (0.78, 1.55) 0.589
Current 1.75 (1.43, 2.16) <0.001 2.04 (1.64, 2.56) <0.001 1.44 (1.08, 1.90) 0.012 5.23 (3.64, 7.52) <0.001 1.33 (1.00, 1.77) 0.050
Ex-smoker 1.43 (1.19, 1.73) <0.001 1.71 (1.38, 2.11) <0.001 1.63 (1.28, 2.08) <0.001 2.95 (2.04, 4.25) <0.001 1.16 (0.89, 1.50) 0.283
Never (ref) 1 1 1 1 1
Deprivation at diagnosis 0.001 <0.001 0.001 0.083 0.403
Most deprived 1.78 (1.35, 2.34) <0.001 1.75 (1.31, 2.34) <0.001 1.73 (1.17, 2.55) 0.006 1.06 (0.74, 1.53) 0.738 1.44 (1.00, 2.07) 0.052
2 1.59 (1.20, 2.09) 0.001 1.55 (1.15, 2.08) 0.003 1.81 (1.23, 2.66) 0.003 0.71 (0.48, 1.05) 0.087 1.22 (0.84, 1.77) 0.290
3 1.57 (1.19, 2.09) 0.002 1.26 (0.93, 1.73) 0.142 2.24 (1.52, 3.30) <0.001 0.76 (0.50, 1.13) 0.174 1.24 (0.85, 1.83) 0.271
4 1.38 (1.02, 1.85) 0.035 1.154 (0.83, 1.59) 0.400 1.51 (1.00, 2.28) 0.052 0.82 (0.55, 1.24) 0.347 1.21 (0.82, 1.80) 0.337
Least deprived (ref) 1 1 1 1 1
Anti-DM med groups
(2 years)
<0.001 <0.001 <0.001 <0.001 0.002
Insulin comb 3.41 (1.71, 6.78) <0.001 4.14 (2.24, 8.04) <0.001 5.51(2.59, 11.72) <0.001 5.12(1.97, 13.30) 0.001 4.83(1.88, 12.39) 0.001
Sulphonylurea comb 1.81 (1.33, 2.45) <0.001 1.59 (1.13, 2.26) 0.009 2.03 (1.36, 3.04) 0.001 2.21 (1.33, 3.6) 0.002 2.01 (1.25, 3.24) 0.004
Glitazone comb 1.38 (0.74, 2.57) 0.317 1.02 (0.49, 2.12) 0.965 1.01 (0.40, 2.53) 0.990 0.33 (0.05, 2.40) 0.272 1.93 (0.81, 4.60) 0.137
Metformin only 1.03 (0.79, 1.33) 0.846 0.93 (0.68, 1.26) 0.620 0.92 (0.63, 1.33) 0.640 1.00 (0.63, 1.60) 0.998 1.20 (0.79, 1.82) 0.406
No drugs (ref) 1 1 1 1 1
Weight change (2 years) 0.731 0.627 0.961 0.173 1.00
Stable-steady 0.86 (0.55, 1.33) 0.485 0.98 (0.62, 1.54) 0.931 0.97 (0.54, 1.77) 0.931 1.61 (0.87, 2.98) 0.132 0.97 (0.50, 1.89) 0.939
Stable-cyclic 0.83 (0.57, 1.19) 0.304 0.76 (0.50, 1.16) 0.201 0.86 (0.51, 1.47) 0.591 0.77 (0.40, 1.50) 0.439 1.00 (0.57, 1.74) 0.998
Gain 0.98 (0.69, 1.37) 0.888 0.94 (0.64, 1.39) 0.768 0.96 (0.59, 1.55) 0.861 0.81 (0.43, 1.55) 0.527 0.99 (0.57, 1.71) 0.963
Loss (ref) 1 1 1 1 1
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potential confounding of treatment on weight change.
All models were adjusted for characteristics at diagnosis
(age, BMI, sex, smoking status and deprivation), vari-
ables known to potentially effect HbA1C and change in
weight. Table 3 presents RRs for all follow-up periods.
Generally younger patients and/or those with higher
baseline BMI had increased risk of ‘not being in
control’ later. Sex, smoking status and deprivation were
generally not significant factors. However, being on anti-
diabetic medication was associated with being ‘not in
control’ (eg, those on insulin at 2 years were four times
more likely to have higher HbA1c and have weight
gain). Compared with weight loss or even stable-steady,
the weight gain and stable-cyclic groups were more likely
to have higher HbA1c levels. However, larger weight var-
iations were more related to HbA1c being ‘in control’.
There were also positive associations for better HbA1c
control with the drug–weight change interactions (gain
with SU or glitazone combinations) compared with the
weight loss or not on drugs groups.
Table 4 gives the hazard rates for all-cause mortality and
the different cardiovascular outcomes (MI, CHF, periph-
eral vascular disease and cerebrovascular disease) adjusted
for patient characteristics, weight change patterns and
antidiabetic medication regimes. It shows similar risk
factors across the different health outcomes. All were asso-
ciated with increasing age, being male (except cerebrovas-
cular disease), smoking (even ex-smokers, although not
for cerebrovascular disease) and increased deprivation
(not for peripheral vascular disease and cerebrovascular
disease). Morbid obesity (BMI≥40) at diagnosis was asso-
ciated with higher risks for mortality and CHF than being
overweight (BMI 25–29.9).
Across all outcomes, insulin combinations were 3–5
times associated with increased mortality risk compared
with the no drug group, while SU combinations had
even greater associations with mortality and CHF.
Although included, good glycaemic control at 2 years
was not significant with respect to these later health out-
comes. Weight change itself was not statistically asso-
ciated, but weight variability was a significant risk factor
related to mortality, and to a lesser extent for MI and
CHF. Drug–weight interactions were investigated, but
none were statistically significant (only overall p values
are given).
DISCUSSION
This study examined weight change patterns in a large
contemporary cohort of overweight or obese patients
newly diagnosed with type 2 diabetes. The weight loss
benefits on glycaemic control and decreased need for
antihyperglycaemic therapy are well documented,12 20
along with reduced disability risks.5 The national
Scottish guidelines recommend that obese adults with
type 2 diabetes should be offered individualised inter-
ventions to encourage weight loss.21 While we found the
mean percentage weight change after 2 years was only
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−0.7±6.7% (persisting up to 5 years), a subgroup (36%)
had lost weight by 2 years with 59.2% of them losing
more than 5%; the corresponding figures by 5 years
were 41% and 68%, respectively. Women were more
likely to lose 5% or more weight than men over the
5 years. Older people (60 years+) and people with
higher initial BMIs were also more likely to lose weight.
This weight lost suggests real effort from this subgroup,
especially since some diabetic treatments induce weight
gain; moreover weight tends to increase over time in the
general population.22 Morgan et al23 showed weight
increases over 1995–2010 for those first diagnosed with
type 2 diabetes.
In this cohort, those younger at diagnosis were signifi-
cantly more obese with higher HbA1c levels. However,
around 36% of the entire cohort had ‘in control’
HbA1c levels (≤7% or 53 mmol/mol) at diagnosis,
increasing to 47% after 5 years. This was more likely for
patients with significant weight loss or the weight stable-
steady group, irrespective of antihyperglycaemic medica-
tion. By 2 and 5 years, 13% and 8%, respectively, had
good glycaemic control (HbA1c<6.5% or 48 mmol/mol)
without diabetic medication. Mean HbA1c was lowest for
those with 10% weight loss and highest for those with
10% weight gain. Best glycaemic control was associated
with metformin, particularly if with weight loss. de Fine
Olivarius et al24 also found weight loss common for
diabetics within 5 years of diagnosis, but did not find
weight affected by SU treatment combinations. In con-
trast, we found insulin, SU and glitazone combinations
all to be associated with weight gain, albeit with better
glycaemic control. What cannot be determined is the
casual path of these factors.
Factors associated with poor control (HbA1c>7% or
53 mmol/mol) at 5 years included being younger,
having a higher diagnosis BMI and to a lesser extent
being female and/or deprived. Perhaps contradictory
are the coefficient of variation results where large weight
variation was associated with better glycaemic control.
However, the direction of the weight change is indistin-
guishable here. ‘Control’ was associated with progressive
weight loss and also with weight gain when combined
with antidiabetic medication. The better glycaemic
control seen for the interaction between diabetic medi-
cation and weight gain may also be due to medication
rather than increased weight. Other explanatory factors
include differences in lifestyle, medication adherence,
response to medication or the propensity for side
effects.25 26
Higher mortality and cardiac failure after 2 years were
also associated with severe obesity (BMI≥40) at diagnosis
(table 4). HbA1c control at 2 years was not related to
any of these outcomes, perhaps because glycaemic
control often includes insulin and SU use, themselves
associated with adverse prognosis and confounding the
results. Weight change at 2 years was also not signifi-
cantly associated with these outcomes. However, weight
variability was significant, with mortality risk for the
weight stable-cyclic group being double that of the
weight loss group. Similar associations were seen for MI
and cardiac failure. Weight variability may reflect other
illnesses, themselves associated with poorer outcomes.
What cannot be determined from these data is if weight
change was intentional. It is known that unintentional
weight loss is often the result of illness.14 While we have
excluded those who died within the first 2 years, we
cannot exclude significant comorbidity that might be
contributing to the variability.
This study may be limited by the observational nature
of the data. However, access to such a large community-
based population is rare and provides detailed investiga-
tive opportunities. While the proportion of data exclu-
sions seems large, this is common for routinely collected
data often subject to incomplete data or input errors.
Reassuringly, the characteristics of patients satisfying the
per-protocol inclusion criteria were compared with those
subsequently excluded for data cleaning reasons, with
no clinically important differences. Further, the
characteristics of this selected cohort after data cleaning
and clinical exclusions are consistent with previous char-
acterisation from the SCI-DC registry14 suggesting they
reflect the general diabetic population in Scotland.
It was difficult to separate the effects of glycaemic
control, treatment and weight change.23 While 30% had
no glucose-lowering drugs after 2 years, this was only
19% after 5 years. Sinclair et al27 noted that only 51% of
patients in their study had antihyperglycaemic medica-
tion within 2 years of diagnosis. These treatments are
generally associated with weight loss (eg, metformin) or
gain (eg, insulin, SUs, glitazones) seen here and else-
where.28 Unfortunately, our cohort did not include
patients on the newer treatments in sufficient numbers
suitable for analysis, for example, glucagon-like
peptide-1 receptor agonists, gliptins. We also did not
examine the effect of blood pressure and lipids along
with their associated treatment regimens. Obesity was
measured by BMI, since other variables like waist circum-
ference were not available.
In line with other studies, we found encouraging rela-
tionships between long-term weight loss, better gly-
caemic control and less antidiabetic medication.
Feldstein et al7 in their small US study, speculated that
the initial period after diagnosis of type 2 diabetes may
be critical for weight loss interventions to improve gly-
caemia and risk factor control, based on a retrospective
cohort—those with weight loss in the first 18 months,
even with regain, had better glycaemic and blood pres-
sure control in the second 18 months. Conversely,
Fumelli et al29 in Italy did not find BMI change and
HbA1c associations over 3 years. However, this was a
small, poor quality study. Like our study, the US study4
found women and older people more likely to achieve
weight loss, with our research highlighting the need to
better support some patients less likely to do well.
Janghorbani et al30 examined predictors of weight
change in type 2 diabetes in an Iranian population over
12 Aucott LS, et al. BMJ Open 2016;6:e010836. doi:10.1136/bmjopen-2015-010836
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9 years. While they did not find BMI>40 predicted
greater weight loss, they did agree with our findings that
women were more likely to lose the most weight, and
insulin is likely to be associated with poor glycaemic
control and weight loss. Another paper by Janghorbani
et al31 found that insulin tended to improve HbA1c with
weight gain, possibly related to better glycaemic control.
The impact of weight loss on mortality in type 2 diabetes
is a subject of debate. Here we saw weight loss benefits
and increased mortality risks with large weight change
variability. A review of six published observational
studies showed divergent results on the topic with one
study showing no association between weight loss and
longevity, two associated weight loss with decreased mor-
tality, one with increased mortality and two reported
varying mortality outcomes in different subgroups.32 In
a smaller older cohort, poorer glycaemic control at diag-
nosis adversely affected survival, but weight loss in the
first year was associated with improved survival.33 Logue
et al,34 using an earlier cross-sectional study in same dia-
betes register database used here, found the highest
mortality for those with BMI≥35, and increasing vascular
mortality BMI≥30, but did not examine weight change.
Carnethon et al35 found that type 2 diabetics with
BMI<25 at diagnosis had the highest total and non-
cardiovascular mortality, but was a relatively small under-
powered study and may instead reflect differing genetic
predisposition to diabetes and other underlying ill-
nesses, a group we excluded because of the higher
chance of misdiagnosis. Our focus was on weight change
patterns, but this apparent adverse effect of SUs and
other antidiabetic medications on mortality has been
described elsewhere including metformin, as discussed
by Roumie et al.36
To date, weight cycling has been alluded to as being
important but without there being any standard defini-
tions or consistency of results. Mehta et al37 recently
undertook a systematic review of the impact of weight
cycling on the risk of morbidity and mortality finding
limited evidence to support any adverse effects of weight
cycling. One US study by Arnold et al38 found an associ-
ation between weight variability/cycling with physical
functioning and mortality in an older group of indivi-
duals but not all had type 2 diabetes. Our study investi-
gated this in more detail for patients with diabetes and
suggests that weight cycling is generally detrimental for
those who are overall weight stable.
Our results show that substantial weight loss is achieved
by a significant proportion of patients receiving standard
care within Scotland. We highlight the significance of
weight loss on improving HbA1c, thus indicating the
importance of diabetes services in promoting intentional
weight loss after diagnosis of type 2 diabetes. One such
trial actively testing this is now in progress.39 Provision for
maintenance strategies are also needed since weight sta-
bility with notable weight variability may be detrimental.
Further, we have identified specific target groups who
would benefit from access to more structured
interventions for weight loss, these being younger
patients with higher BMIs, and also men and those from
more deprived communities. Within Scotland, there is
now a process to review patient education programmes
and whether they meet structured education criteria.40
Our results should be considered within such processes.
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